# Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

- Link: https://www.thailand-business-news.com/pr-news/antengene-to-present-latest-preclinical-results-of-novel-cos-tce-platform-in-rapid-oral-abstract-presentation-at-sitc-2026
- Published: 2026-10-03T07:30:00+07:00
- Author: PR Newswire

|   |

SHANGHAI and HONG KONG, Oct. 3, 2026 /PRNewswire/ — Antengene Corporation Limited(**"
Antengene"**, SEHK: 6996.HK), a leading innovative, commercial-stage global biotech
company dedicated to discovering, developing and commercializing first-in-class 
and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological
malignancies, today announced that** it will present the latest preclinical results
of its novel costimulatory T cell engager (Cos-TCE) platform in a Rapid Oral Abstract
Presentation at the 2026 Society for Immunotherapy of Cancer Annual Meeting (SITC
2026)**, taking place from November 4^(th) to 8^(th), 2026, at the Phoenix Convention
Center, Phoenix, Arizona, U.S.

**Details of the Poster Presentation**

**Title: **A CD2-based costimulatory T cell engager platform integrating a novel
CD3γε/δε-targeting antibody and steric-hindrance-based CD3 masking
**Abstract: **
15749

**Rapid Oral Abstract Presentation**

**Presenting Author: **Dr. Bing Hou, Antengene’s Chief Scientific Officer
**Topic
Selection: **Rapid Oral – Basic 1**Date: **Friday, November 6, 2026**Time: **12:
30 PM – 01:30 PM (Eastern Time)          01:30 AM – 02:30 AM , November 7 (Beijing
Time)

**About Antengene**

Antengene Corporation Limited ("**Antengene**", SEHK: 6996.HK) is a global, R&D-
driven, commercial-stage biotech company focused on developing first-in-class/best-
in-class therapeutics for diseases with significant unmet medical needs. Its pipeline
spans from preclinical to commercial stages, with key investigational candidates
including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 
x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-
TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed
using Antengene’s proprietary AnTenGager^(®) platform.

AnTenGager^(®), is Antengene’s proprietary TCE 2.0 platform, featuring "2+1" bivalent
binding for low expressing targets, steric hindrance masking, and proprietary CD3
sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) 
and enhance efficacy. These characteristics support the platform’s broad applicability
across autoimmune diseases, solid tumors and hematological malignancies, with programs
targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases; partnered 
with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer; partnered with
K2 Therapeutics established by MPM BioImpact), ALPPL2 x CD3 (ATG-112 for gynecological
tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (
ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for 
multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic 
myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).

To date, Antengene has obtained 35 investigational new drug (IND) approvals in the
U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific
markets. Its lead commercial asset, XPOVIO^(® )(selinexor), is approved in the Mainland
of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia,
Thailand, Indonesia and Australia, and has been included in the national insurance
schemes in five of these markets (Mainland of China, Taiwan China, Australia, South
Korea and Singapore).

**Forward-looking statements**

The forward-looking statements made in this article relate only to the events or
information as of the date on which the statements are made in this article. Except
as required by law, we undertake no obligation to update or revise publicly any 
forward-looking statements, whether as a result of new information, future events
or otherwise, after the date on which the statements are made or to reflect the 
occurrence of unanticipated events. You should read this article completely and 
with the understanding that our actual future results or performance may be materially
different from what we expect. In this article, statements of, or references to,
our intentions or those of any of our Directors or our Company are made as of the
date of this article. Any of these intentions may alter in light of future development.
For a further discussion of these and other factors that could cause future results
to differ materially from any forward-looking statement, please see the other risks
and uncertainties described in the Company’s Annual Report for the year ended December
31, 2025, and the documents subsequently submitted to the Hong Kong Stock Exchange.

**For more information, please contact:**

**PR / IR Contacts: **
Peter QianE-mail: [peter.qian@antengene.com](https://www.thailand-business-news.com/pr-news/peter.qian@antengene.com)

**BD Contacts:**
Ariel GuoE-mail: [ariel.guo@antengene.com](https://www.thailand-business-news.com/pr-news/ariel.guo@antengene.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026 ](http://www.prnasia.com/story/archive/5057711_AE57711_0?rand=184833)
